Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer

Background: The combination of CDK4/6 inhibitors and endocrine therapy has greatly improved progression-free survival (PFS) in patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer in many randomized controlled trials (RCTs). Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Mingxi, Chen, Yang, Jin, Yizi, Hu, Xichun, Zhang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646186/
https://www.ncbi.nlm.nih.gov/pubmed/33193875
http://dx.doi.org/10.7150/jca.48944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646186/
https://www.ncbi.nlm.nih.gov/pubmed/33193875
http://dx.doi.org/10.7150/jca.48944

Ejemplares similares